Robert F Graziano

Learn More
BACKGROUND Severe acute respiratory syndrome (SARS) remains a significant public health concern after the epidemic in 2003. Human monoclonal antibodies (MAbs) that neutralize SARS-associated coronavirus (SARS-CoV) could provide protection for exposed individuals. METHODS Transgenic mice with human immunoglobulin genes were immunized with the recombinant(More)
CD30 is a promising target for antibody-based immunotherapy of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma. To overcome the limitations from currently available murine anti-CD30 monoclonal antibodies (mAbs), a new fully human anti-CD30 antibody was generated. Binding properties were evaluated by recombinant CD30 capture enzyme-linked(More)
  • Pina M Cardarelli, Maria-Cristina Moldovan-Loomis, +11 authors David J King
  • 2009
PURPOSE This study was undertaken to evaluate the effects of MDX-1401, a nonfucosylated fully human monoclonal antibody that binds to human CD30, and to determine whether it exhibits greater in vitro and in vivo activity than its parental antibody. EXPERIMENTAL DESIGN Assays measuring antibody binding to CD30-expressing cells and FcgammaRIIIa (CD16)(More)
Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/ IPH2102) in a preclinical xenograft tumor model Natural Killer cells (NK cells) are lymphocytes able to recognize and kill tumors for which the expression of Major Histocompatibility Complex (MHC) class I molecules is altered. This " missing self " recognition is mediated in(More)
  • 1